Business Context and Reporting Period
Zimmer Holdings, Inc. (now Zimmer Biomet Holdings, Inc.) filed this Form 8-K on April 26, 2006, to report its results of operations for the quarter ended March 31, 2006. The company, incorporated in Delaware, is headquartered in Warsaw, Indiana. This filing incorporates by reference an earnings release (Exhibit 99.1) containing detailed financial data.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the attached press release (Exhibit 99.1) which is incorporated by reference but not reproduced in this document.
The company reports the following non-GAAP financial measures in its earnings release:
- Adjusted net earnings and adjusted diluted EPS (excluding acquisition/integration expenses and inventory step-up).
- Adjusted net margin, adjusted operating margin, and adjusted gross margin.
- Constant currency sales (excluding foreign exchange rate impacts).
Material Changes and Accounting Adjustments
The quarter ended March 31, 2006, marks the first period in which the company's financial results include share-based payment expenses resulting from the adoption of the new accounting standard SFAS 123(R), "Share-Based Payment."
To facilitate comparison with prior periods that did not include SFAS 123(R) charges, the company has disclosed adjusted non-GAAP measures that exclude the effect of share-based payments. Additionally, the company continues to exclude acquisition and integration expenses related to its 2003 acquisition of Centerpulse AG and its 2004 acquisition of Implex Corp. from its adjusted metrics.
Guidance, Outlook, and Management Commentary
Management states that the presentation of these non-GAAP measures allows investors to compare performance on a period-to-period basis and understand operating results absent specific acquisition-related items and the impact of SFAS 123(R). The filing explicitly notes that these non-GAAP measures should be considered in addition to, and not as a substitute for, GAAP measures. All non-GAAP measures are reconciled to the most directly comparable GAAP measures in the attached press release.
The filing does not contain specific forward-looking guidance, risk factors, or contingencies beyond the standard disclosures regarding the adoption of new accounting standards.
Investor Verification Checklist
- Verify the specific GAAP revenue, net income, and EPS figures in the attached Exhibit 99.1 press release.
- Review the reconciliation tables in the press release to understand the magnitude of the SFAS 123(R) share-based payment charges.
- Confirm the impact of foreign currency exchange rates on sales by comparing reported sales to constant currency sales.
- Assess the specific acquisition and integration expenses excluded from the adjusted non-GAAP metrics.